RICARDO ROMITI

(Fonte: Lattes)
Índice h a partir de 2011
22
Lattes
Projetos de Pesquisa
Unidades Organizacionais
Instituto Central, Hospital das Clínicas, Faculdade de Medicina
LIM/53 - Laboratório de Micologia, Hospital das Clínicas, Faculdade de Medicina
LIM/50 - Laboratório de Patologia das Moléstias Infecciosas, Hospital das Clínicas, Faculdade de Medicina

Filtros

Mostrar mais
Limpar filtros

Configurações

Autor: VALENZUELA, Fernando × Indexador: MEDLINE ×

Resultados de Busca

Agora exibindo 1 - 7 de 7
  • conferenceObject
    Psoriasis And Mental Health Comorbidities: A Multinational Analysis Using the Global Healthcare Study on Psoriasis (GHSP)
    (2023) PETERSON, Hannah; KOROURI, Edwin; KINGSTON, Paige; LEE, Kathryn; HUANG, Margaret; YEE, Danielle; AGUERO, Rosario; ARTIGA, Kevin; VALENZUELA, Fernando; ROMITI, Ricardo; DIDASKALU, Johannes; EGEBERG, Alexander; OON, Hazel H.; MAUL, Julia-Tatjana; ARMSTRONG, April W.
  • article 3 Citação(ões) na Scopus
    Comorbidities in Chilean patients with psoriasis: a Global Healthcare Study on Psoriasis
    (2022) VALENZUELA, Fernando; CRUZ, Claudia De La; LECAROS, Cristobal; FERNANDEZ, Javier; HEVIA, Gonzalo; MAUL, Lara Valeska; THYSSEN, Jacob P.; VERA-KELLET, Cristian; EGEBERG, Alexander; ARMIJO, Daniela; PIZARRO, Cristian; RIVEROS, Tatiana; CORREA, Hernan; GUGLIELMETTI, Antonio; DIDASKALU, Johannes A.; WU, Jashin J.; GRIFFITHS, Christopher E. M.; ROMITI, Ricardo; MAUL, Julia-Tatjana
    Background Psoriasis is a chronic inflammatory skin disease associated with several important medical comorbidities. There are scant data available on the comorbidities of patients with psoriasis in South America. Aim To examine the comorbidity profile of adult patients with psoriasis in Chile and its association with severity of psoriasis. Methods This was a multicentre, cross-sectional study involving 16 hospitals and clinics in Chile, which used a 48-item questionnaire to study clinician- and patient-reported outcomes and comorbidities. Inferential analyses were performed by psoriasis severity, using Fisher exact test, Student t-test and multivariable logistic regression. Results In total, 598 adult patients with psoriasis were included (51.1% male; mean age 49.2 +/- 15.1 years); 48.5% mild and 51.4% moderate to severe; Psoriasis Area and Severity Index 11.6 +/- 11.5; body surface area 14.7 +/- 18.2%. Plaque psoriasis was the most common phenotype (90.2%), followed by guttate (13.4%). Psoriatic arthritis occurred in 27.3% of patients. Comorbidities were reported in 60.2% of all patients with psoriasis. Frequent concomitant diseases were obesity (25.3%), hypertension (24.3%), Type 2 diabetes mellitus (T2DM) (18.7%), dyslipidaemia (17.4%), metabolic syndrome (16.7%) and depression (14.4%). After adjustment, significant associations were found between moderate to severe psoriasis and obesity, T2DM and nonalcoholic fatty liver disease (NAFLD) compared with mild psoriasis. Conclusions We report a large study of comorbidities, including depression, dyslipidaemia, T2DM and NAFLD, in people with psoriasis in Chile. The prevalence of comorbidities with psoriasis in Chile appears similar to that found in Western countries, and emphasizes the importance of assessing patients with psoriasis for risk factors for and presence of, comorbid disease in a multidisciplinary setting.
  • article 2 Citação(ões) na Scopus
    Access to psoriasis treatment in Brazil and Chile: A cross-sectional multicentre Global Healthcare Study on Psoriasis
    (2023) MAUL, Julia-Tatjana; FROEHLICH, Fabienne; MAUL, Lara Valeska; STUNNENBERG, Rieka; VALENZUELA, Fernando; CRUZ, Claudia De La; VERA-KELLET, Cristian; ARMIJO, Daniela; CESAR, Wagner G.; CARVALHO, Andre; DIDASKALU, Johannes Alexander; GRAF, Nicole; EGEBERG, Alexander; WU, Jashin J.; THYSSEN, Jacob P.; ROMITI, Ricardo; GRIFFITHS, Christopher E. M.
    Background Sufficient data on access to systemic treatment for patients with psoriasis living in Latin America (LA) including Brazil and Chile are lacking. Understanding the availability and limiting factors of access to treatments can help to improve patient care and decrease long-term healthcare costs. Objectives In association with the Global Psoriasis Atlas, this cross-sectional survey study analysed the availability and insurance reimbursement of systemic treatments for adult patients with psoriasis in Brazil and Chile. Methods A multicentre, cross-sectional Global Healthcare Study on Psoriasis was performed in Brazil and Chile in 2020. For each eligible adult patient with psoriasis, doctors and nurses completed a 48-item questionnaire about clinical aspects of psoriasis including the Psoriasis Area Severity Index (PASI), body surface area (BSA) score and the Dermatology Life Quality Index (DLQI), as well as the availability of systemic treatments and insurance reimbursement status. Between-country differences were compared with Wilcoxon rank sum tests for continuous variables, and a chi(2)-test or Fisher's exact test, where appropriate, for categorical variables. The median and interquartile range (IQR) was calculated for non-normal distributed data. Results A total of 1424 patients with psoriasis from 43 centres [27 centres in Brazil (n = 826) and 16 in Chile (n = 598)], were included with a mean (SD) age of 49.1 (16.3) and 49.2 (15.1) years, respectively. Unstratified analyses revealed that patients with psoriasis in Chile had more severe disease than those in Brazil [PASI 11.6 vs. 8.4 (P < 0.001) and BSA 14.7 vs. 12.0 (P = 0.003), respectively]. For patients with moderate-to-severe psoriasis, defined as PASI and/or BSA >= 10, systemic nonbiologic drugs were available (81.2% in Brazil and 65.3% in Chile, P <= 0.001), but only 37.0% of patients in Brazil and 27.3% in Chile received biologics (P = 0.01). Lack of availability and/or lack of insurance reimbursement for biologic drugs for patients with moderate-to-severe psoriasis was reported for 22.2% (50 of 225) in Brazil and 67.9% (148 of 218) in Chile (P < 0.001). Patients with no access to biologic therapies due to lack of availability/insurance reimbursement had a median PASI of 9.15 (IQR 3.00-14.25) in Brazil and 12.0 (IQR 5.00-19.00) in Chile (P = 0.007), as well as a median BSA of 7.0 (IQR 3.00-15.00) and 12.0 (IQR 5.00-22.50) (P = 0.002), and median DLQI of 11.0 (6.00-15.00) and 21.0 (6.50-25.00) (P = 0.007), respectively. Conclusions Chilean patients had significantly more severe psoriasis compared with Brazilian patients in our study. While nonbiologic treatments for moderate-to-severe psoriasis were available in both LA countries, there is a high need for improvement in access to more effective psoriasis treatments including biologics. Our results highlight a significant gap between treatment recommendations in international psoriasis guidelines and real-world situations in Brazil and Chile.
  • article 0 Citação(ões) na Scopus
    Correlation between Dermatology Life Quality Index and Psoriasis Area and Severity Index in Patients with Psoriasis: A Cross-sectional Global Healthcare Study on Psoriasis
    (2024) MAUL, Julia-Tatjana; V, Lara Maul; DIDASKALU, Johannes A.; VALENZUELA, Fernando; ROMITI, Ricardo; PETERSON, Hannah; KOROURI, Edwin; NOVOA, Farah; OON, Hazel H.; ZHENG, Min; WU, Jashin J.; THYSSEN, Jacob P.; EGEBERG, Alexander; ARMSTRONG, April W.; NIELSEN, Mia-Louise
    Quality of life impairment in dermatology patients and severity of psoriasis are quantified by the Dermatology Life Quality Index (DLQI) and the Psoriasis Area and Severity Index (PASI), respectively. The aim of this study is to compare the correlation between PASI and DLQI in patients from different geographical areas and to identify predictors of high DLQI across geographical regions. Correlations between PASI and DLQI were evaluated using Spearman's rank correlation tests and quantile regression. The study included 1,158 patients with psoriasis, with a median (interquartile range) PASI and DLQI of 6.0 (3.0-12.0) and 8.0 (4.0-15.0), respectively. Correlations were demonstrated between PASI and DLQI, both overall and stratified by geographical region. Quantile (median) regression yielded coefficients of 0.75 (95% confidence interval (95% CI) 0.62, 0.88) for Switzerland, 0.50 (95% CI 0.42, 0.58) for Latin America, 0.34 (95% CI 0.16, 0.51) for Asia, and 0.31 (95% CI 0.08, 0.53) for the USA. Current age, age at diagnosis, sex, body mass index, and psoriasis arthritis affected DLQI in Latin America, while education had an impact among patients treated in Switzerland. Few countries were included within each continent; hence, more data from different countries are necessary for generalizability. The study showed correlations between PASI and DLQI among patients in all included geographical regions. The patients' characteristics affecting DLQI vary worldwide.
  • conferenceObject
    Correlation between DLQI and PASI in patients with psoriasis - a cross-sectional Global Healthcare Study on Psoriasis (GHSP)
    (2023) NIELSEN, Mia-Louise; MAUL, Lara Valeska; DIDASKALU, Johannes A.; VALENZUELA, Fernando; ROMITI, Ricardo; GRIFFITHS, Christopher E. M.; NOVOA, Farah; OON, Hazel H.; EGEBERG, Alexander; ARMSTRONG, April W.; MAUL, Julia-Tatjana
  • conferenceObject
    Comparison of COVID-19 Vaccination Rates Among Psoriasis Patients Globally Using the Global Healthcare Study on Psoriasis (GHSP)
    (2023) KOROURI, Edwin; PETERSON, Hannah; VALENZUELA, Fernando; ROMITI, Ricardo; DIDASKALU, Johannes; EGEBERG, Alexander; OON, Hazel H.; YEE, Danielle; ARTIGA, Kevin; AGUERO, Rosario; KINGSTON, Paige; LEE, Kathryn; HUANG, Margaret Y.; MAUL, Julia-Tatjana; ARMSTRONG, April W.
  • article 15 Citação(ões) na Scopus
    Biosimilars in psoriasis: Clinical practice and regulatory perspectives in Latin America
    (2017) CRUZ, Claudia de la; CARVALHO, Andre V. E. de; DORANTES, Gladys L.; GARCIA, Angela M. Londono; GONZALEZ, Cesar; MASKIN, Matias; PODOSWA, Nancy; REDFERN, Jan S.; VALENZUELA, Fernando; WALT, Joelle van der; ROMITI, Ricardo
    Latin American countries view biosimilar agents as an effective approach to curtail health-care expenditures while maintaining the safety and efficacy profile of their branded innovator comparators. To understand the complexities of the regulatory landscape and key therapeutic issues for use of biosimilars to treat moderate to severe psoriasis in Latin America, the International Psoriasis Council convened dermatology experts from Argentina, Brazil, Chile, Colombia and Mexico in October 2015 to review the definition, approval, marketing and future of biosimilars in each country and develop a consensus statement. The regulatory framework for marketing approval of biosimilars in Latin America is currently a mosaic of disparate, country-specific, regulatory review processes, rules and standards, with considerable heterogeneity in clarity and specificity. Regulations in Argentina, Brazil, Chile and Mexico have undergone multiple refinements whereas Colombia is finalizing draft guidelines. Verification of the similarity in quality, safety and efficacy of biosimilars to the innovator biologic remains a key challenge for policy makers and regulatory authorities. Other key regulatory challenges include: naming of agents and traceability, pharmacovigilance, extrapolation of indications, and interchangeability and substitution. An urgent need exists for more Latin American countries to establish national psoriasis registries and to integrate their common components into a multinational psoriasis network, thereby enhancing their interpretative power and impact. A Latin American psoriasis network similar to PSONET in Europe would assist health-care providers, pharmaceutical companies, regulators and patients to fully comprehend specific products being prescribed and dispensed and to identify potential regional trends or differences in safety or outcomes.